Translational concepts of mglur5 in synaptic diseases of the brain

Frontiers in Pharmacology

Volumn 3 NOV, Issue , 2012, Pages

  Piers, Thomas M ^a   Kim, Dong Hyun ^a   Kim, Byeong C ^a,b   Regan, Philip ^a,c,d   Whitcomb, Daniel J ^a   Cho, Kwangwook ^a,c  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b Chonnam National University Medical School   (South Korea)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

MGluR5; Scaffolding proteins; Synaptic disease

Indexed keywords

AMYLOID BETA PROTEIN; CARRIER PROTEIN; CYCLIN DEPENDENT KINASE 5; METABOTROPIC RECEPTOR 5; POSTSYNAPTIC PROTEIN; PRESO1; PROTEIN HOMER; SCAFFOLD PROTEIN; SH3 MULTIPLE ANKYRIN DOMAIN CONTAINING PROTEIN; UNCLASSIFIED DRUG; VOLTAGE GATED CALCIUM CHANNEL;

ALZHEIMER DISEASE; ARTICLE; BRAIN DISEASE; DEVELOPMENTAL DISORDER; HUMAN; INTRACELLULAR SIGNALING; MENTAL DISEASE; MOLECULAR PATHOLOGY; NERVE CELL PLASTICITY; NEUROTOXICITY; NONHUMAN; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; SYNAPTIC BRAIN DISEASE; SYNAPTIC TRANSMISSION; SYNAPTOGENESIS;

EID: 84870658352     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2012.00199     Document Type: Article

References (86)

1. Anwyl, R. (1992). Metabotropic gluta-mate receptors: electrophysiological properties and role in plasticity. Rev. Neurosci. 3, 217-231.
2. Aronica, E., Catania, M. V., Geurts, J., Yankaya, B., and Troost, D. (2001). Immunohistochemical localization of group I and II metabotropic glutamate receptors in control and amyotrophic lateral sclerosis human spinal cord: upregulation in reactive astrocytes. Neuroscience 105, 509-520.
3. Attucci, S., Carla, V., Mannaioni, G., and Moroni, F. (2001). Activation of type 5 metabotropic glutamate receptors enhances NMDA responses in mice cortical wedges. Br. J. Pharmacol. 132, 799-806.
4. Awad, H., Hubert, G. W., Smith, Y., Levey, A. I., and Conn, P. J. (2000). Activation of metabotropic gluta-mate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus. J. Neurosci. 20, 7871-7879.
5. Bashir, Z. I., Bortolotto, Z. A., Davies, C. H., Berretta, N., Irving, A. J., Seal, A. J., et al. (1993). Induction of LTP in the hippocampus needs synaptic activation of glutamate metabotropic receptors. Nature 363, 347-350.
6. Bellone, C., Luscher, C., and Mameli, M. (2008). Mechanisms of synaptic depression triggered by metabotropic glutamate receptors. Cell. Mol. Life Sci. 65, 2913-2923.
7. Berridge, M. J., and Irvine, R. F. (1984). Inositol trisphosphate, a novel second messenger in cellular signal transduction. Nature 312, 315-321.
8. Berthele, A., Platzer, S., Laurie, D. J., Weis, S., Sommer, B., Zieglgans-berger, W., et al. (1999). Expression of metabotropic glutamate receptor subtype mRNA (mGluR1-8) in human cerebellum. Neuroreport 10, 3861-3867.
9. Bortolotto, Z. A., and Collingridge, G. L. (1993). Characterisation of LTP induced by the activation of glu-tamate metabotropic receptors in area CA1 of the hippocampus. Neu-ropharmacology 32, 1-9.
10. Brakeman, P. R., Lanahan, A. A., O'Brien, R., Roche, K., Barnes, C. A., Huganir, R. L., et al. (1997). Homer: a protein that selectively binds metabotropic glutamate receptors. Nature 386, 284-288.
11. Carlisle, H. J., Luong, T. N., Medina-Marino, A., Schenker, L., Khoro-sheva, E., Indersmitten, T., et al. (2011). Deletion of densin-180 results in abnormal behaviors associated with mental illness and reduces mGluR5 and DISC1 in the postsynaptic density fraction. J. Neurosci. 31, 16194-16207
12. Cartmell, J., and Schoepp, D. D. (2000). Regulation of neurotrans-mitter release by metabotropic glu-tamate receptors. J. Neurochem. 75, 889-907.
13. Castiglione, M., Calafiore, M., Costa, L., Sortino, M. A., Nicoletti, F., and Copani, A. (2008). Group I metabotropic glutamate receptors control proliferation, survival and differentiation of cultured neural progenitor cells isolated from the subventricular zone of adult mice. Neuropharmacology 55, 560-567.
14. Catania, M. V., Landwehrmeyer, G. B., Testa, C. M., Standaert, D. G., Penney, J. B. Jr., and Young, A. B. (1994). Metabotropic glutamate receptors are differentially regulated during development. Neuroscience 61, 481-495.
15. Chapman, A. G., Nanan, K., Williams, M., and Meldrum, B. S. (2000). Anticonvulsant activity of two metabotropic glutamate group I antagonists selective for the mGlu5 receptor: 2-methyl-6-(phenylethynyl)-pyridine (MPEP), and (E)-6-methyl-2-styryl-pyridine (SIB 1893). Neuropharmacology 39, 1567-1574.
16. Chen, H. H., Stoker, A., and Markou, A. (2010). The glutamatergic compounds sarcosine and N-acetylcysteine ameliorate prepulse inhibition deficits in metabotropic glutamate 5 receptor knockout mice. Psychopharmacology (Berl.) 209, 343-350.
17. Conn, P. J., Lindsley, C. W., and Jones, C. K. (2009). Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia. Trends Pharmacol. Sci. 30, 25-31.
18. Conn, P. J., and Pin, J. P. (1997). Pharmacology and functions of metabotropic glutamate receptors. Annu. Rev. Pharmacol. Toxicol. 37, 205-237.
19. Di Giorgi Gerevini, V. D., Caruso, A., Cappuccio, I., Ricci Vitiani, L., Romeo, S., Della Rocca, C., et al. (2004). The mGlu5 metabotropic glutamate receptor is expressed in zones of active neurogenesis of the embryonic and postnatal brain. Brain Res.Dev. Brain Res.150,17-22.
20. Di Giorgi-Gerevini, V., Melchiorri, D., Battaglia, G., Ricci-Vitiani, L., Ciceroni, C., Busceti, C. L., et al. (2005). Endogenous activation of metabotropic glutamate receptors supports the proliferation and survival of neural progenitor cells. Cell Death Differ. 12, 1124-1133
21. Dolen, G., and Bear, M. F. (2008). Role for metabotropic glutamate receptor 5 (mGluR5) in the pathogene-sis of fragile X syndrome. J. Physiol. (Lond.) 586, 1503-1508.
22. Dolen, G., Carpenter, R. L., Ocain, T. D., and Bear, M. F. (2010). Mechanism-based approaches to treating fragile X. Pharmacol. Ther. 127, 78-93.
23. Durand, C. M., Perroy, J., Loll, F., Per-rais, D., Fagni, L., Bourgeron, T., et al. (2012). SHANK3 mutations identified in autism lead to modification of dendritic spine morphology via an actin-dependent mechanism. Mol. Psychiatry 17, 71-84.
24. Fisher, A. (2012). Cholinergic modulation of amyloid precursor protein processing with emphasis on M1 muscarinic receptor: perspectives and challenges in treatment of Alzheimer's disease. J. Neurochem. 120(Suppl. 1), 22-33.
25. Gauthier, J., Champagne, N., Lafrenière, R. G., Xiong, L., Spiegelman, D., Brustein, E., et al. (2010). De novo mutations in the gene encoding the synaptic scaffolding protein SHANK3 in patients ascertained for schizophrenia. Proc. Natl. Acad. Sci. U.S.A. 107, 7863-7868.
26. Giuffrida, R., Musumeci, S., D'Antoni, S., Bonaccorso, C. M., Giuffrida-Stella, A. M., Oostra, B. A., et al. (2005). A reduced number of metabotropic glutamate subtype 5 receptors are associated with constitutive homer proteins in a mouse model of fragile X syndrome. J. Neurosci. 25, 8908-8916.
27. Grabrucker, A. M., Schmeisser, M. J., Schoen, M., and Boeckers, T. M. (2011). Postsynaptic ProSAP/Shank scaffolds in the cross-hair of synap-topathies. Trends Cell Biol. 21, 594-603.
28. Gray, L., van den Buuse, M., Scarr, E., Dean, B., and Hannan, A. J. (2009). Clozapine reverses schizophrenia-related behaviours in the metabotropic glutamate receptor 5 knockout mouse: association with N-methyl-D-aspartic acid receptor up-regulation. Int. J. Neuropsychopharmacol. 12, 45-60.
29. Gregory,K. J., Dong,E. N., Meiler, J., and Conn, P. J. (2011). Allosteric modulation of metabotropic glutamate receptors: structural insights and therapeutic potential. Neurophar-macology 60, 66-81.
30. Hauser, W., and Hersdorffer, D. (1990). Epilepsy: Frequency, Causes and Consequences. New York: Demos.
31. Homayoun, H., and Moghaddam, B. (2010). Group 5 metabotropic glutamate receptors: role in modulating cortical activity and relevance to cognition. Eur. J. Pharmacol. 639, 33-39.
32. Homayoun, H., Stefani, M. R., Adams, B. W., Tamagan, G. D., and Moghaddam, B. (2004). Functional interaction between NMDA and mGlu5 receptors: effects on working memory, instrumental learning, motor behaviors, and dopamine release. Neuropsychopharmacology 29, 1259-1269.
33. Hsieh, H., Boehm, J., Sato, C., Iwat-subo, T., Tomita, T., Sisodia, S., et al. (2006). AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron 52, 831-843.
34. Hu, J. H., Yang, L., Kammermeier, P. J., Moore, C. G., Brakeman, P. R., Tu, J., et al. (2012). Preso1 dynamically regulates group I metabotropic glu-tamate receptors. Nat. Neurosci. 15, 836-844.
35. Huang, Y., and Mucke, L. (2012). Alzheimer mechanisms and therapeutic strategies. Cell 148, 1204-1222.
36. Iossifov, I., Ronemus, M., Levy, D., Wang, Z., Hakker, I., Rosenbaum, J., et al. (2012). De novo gene disruptions in children on the autistic spectrum. Neuron 74, 285-299.
37. Jo, J., Ball, S. M., Seok, H., Oh, S. B., Massey,P.V.,Molnar,E.,etal. (2006). Experience-dependent modification of mechanismsof long-term depression. Nat. Neurosci. 9, 170-172.
38. Jo, J.,Whitcomb,D. J., Olsen, K. M., Kerrigan, T. L., Lo, S. C., Bru-Mercier, G., et al. (2011). Abeta(1-42) inhibition of LTP is mediated by a signaling pathway involving caspase-3, Akt1 and GSK-3beta. Nat. Neurosci. 14, 545-547.
39. Joly, C., Gomeza, J., Brabet, I., Curry, K., Bockaert, J., and Pin, J. P. (1995). Molecular, functional, and pharmacological characterization of the metabotropic glutamate receptor type 5 splice variants: comparison with mGluR1. J. Neurosci. 15, 3970-3981.
40. Jong,Y. J., Kumar,V., and O'Malley,K. L. (2009). Intracellular metabotropic glutamate receptor 5 (mGluR5) activates signaling cascades distinct from cell surface counterparts. J. Biol. Chem. 284, 35827-35838.
41. Kammermeier, P. J., and Worley, P. F. (2007). Homer 1a uncouples metabotropic glutamate receptor 5 from postsynaptic effectors. Proc. Natl. Acad. Sci. U.S.A. 104, 6055-6060.
42. Krystal, J. H., Mathew, S. J., D'Souza, D. C., Garakani, A., Gunduz-Bruce, H., and Charney, D. S. (2010). Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists. CNS Drugs 24, 669-693
43. Kumar, V., Fahey, P. G., Jong, Y. J., Ramanan, N., and O'Malley, K. L. (2012). Activation of intracellu-lar metabotropic glutamate receptor 5 in striatal neurons leads to up-regulation of genes associated with sustained synaptic transmission including Arc/Arg3.1 protein. J. Biol. Chem. 287, 5412-5425.
44. Lee, H. G., Ogawa, O., Zhu, X., O'Neill, M. J., Petersen, R. B., Castel-lani, R. J., et al. (2004). Aberrant expression of metabotropic glutamate receptor 2 in the vulnerable neurons of Alzheimer's disease. Acta Neuropathol. 107, 365-371.
45. Lee, R. K., Wurtman, R. J., Cox, A. J., and Nitsch, R. M. (1995). Amyloid precursor protein processing is stimulated by metabotropic gluta-mate receptors. Proc. Natl. Acad. Sci. U.S.A. 92, 8083-8087.
46. Lennertz, L., Wagner, M., Wolwer, W., Schuhmacher, A., Frommann, I., Berning, J., et al. (2012). A promoter variant of SHANK1 affects auditory working memory in schizophrenia patients and in subjects clinically at risk for psychosis. Eur. Arch. Psychiatry Clin. Neurosci. 262, 117-124.
47. Levenga, J., Hayashi, S., de Vrij, F. M., Koekkoek, S. K., van der Linde, H. C., Nieuwenhuizen, I., et al. (2011). AFQ056, a new mGluR5 antagonist for treatment of fragile X syndrome. Neurobiol. Dis. 42, 311-317.
48. Li, S., Hong, S., Shepardson, N. E., Walsh, D. M., Shankar, G. M., and Selkoe, D. (2009). Soluble oligomers of amyloid beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron 62, 788-801.
49. Liu, F., Grauer, S., Kelley, C., Navarra, R., Graf, R., Zhang, G., et al. (2008). ADX47273 [S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: a novel metabotropic gluta-mate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities. J. Pharmacol. Exp. Ther. 327, 827-839.
50. Lopez-Bendito, G., Shigemoto, R., Fairen, A., and Lujan, R. (2002). Differential distribution of group I metabotropic glutamate receptors during rat cortical development. Cereb. Cortex 12, 625-638.
51. Malter, J. S., Ray, B. C., Westmark, P. R., and Westmark,C.J. (2010). Fragile X syndrome and Alzheimer's disease: another story about APP and beta-amyloid. Curr. Alzheimer Res. 7, 200-206.
52. Matta, J. A., Ashby, M. C., Sanz-Clemente, A., Roche, K. W., and Isaac, J. T. (2011). mGluR5 and NMDA receptors drive the experience- and activity-dependent NMDA receptor NR2B to NR2A subunit switch. Neuron 70, 339-351.
53. Mehta, M. V., Gandal, M. J., and Siegel, S. J. (2011). mGluR5-antagonist mediated reversal of elevated stereotyped, repetitive behaviors in the VPA model of autism. PLoS ONE 6, e26077. doi:10.1371/journal.pone.0026077
54. Menard, C., and Quirion, R. (2012). Successful cognitive aging in rats: a role for mGluR5 gluta-mate receptors, homer 1 proteins and downstream signaling pathways. PLoS ONE 7, e28666. doi:10.1371/journal.pone.0028666
55. Minakami, R., Katsuki, F., and Sugiyama, H. (1993). A variant of metabotropic glutamate receptor subtype 5: an evolutionally conserved insertion with no termination codon. Biochem. Biophys. Res. Commun. 194, 622-627.
56. Musumeci, S. A., Colognola, R. M., Ferri, R., Gigli, G. L., Petrella, M. A., Sanfilippo, S., et al. (1988). Fragile-X syndrome: a particular epilep-togenic EEG pattern. Epilepsia 29, 41-47.
57. Niswender, C. M., and Conn, P. J. (2010). Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annu. Rev. Pharmacol. Toxicol. 50, 295-322.
58. O'Leary, D. M., Movsesyan, V., Vicini, S., and Faden, A. I. (2000). Selective mGluR5 antagonists MPEPandSIB-1893 decrease NMDA or glutamate-mediated neuronal toxicity through actions that reflect NMDA receptor antagonism. Br. J. Pharmacol. 131, 1429-1437.
59. Two distinct forms of long-term depression coexist in CA1 hippocampal pyramidal cells
60. Park, H., Varadi, A., Seok, H., Jo, J., Gilpin, H., Liew, C. G., et al. (2007). mGluR5 is involved in den-drite differentiation and excitatory synaptic transmission in NTERA2 human embryonic carcinoma cell-derived neurons. Neuropharmacol-ogy 52, 1403-1414.
61. Pisani, A., Gubellini, P., Bonsi, P., Con-quet, F., Picconi, B., Centonze, D., et al. (2001). Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-D-aspartate responses in medium spiny striatal neurons. Neuroscience 106, 579-587
62. Rammes, G., Hasenjager, A., Sroka-Saidi, K., Deussing, J. M., and Parsons, C. G. (2011). Therapeutic significance of NR2B-containing NMDA receptors and mGluR5 metabotropic glutamate receptors in mediating the synaptotoxic effects of beta-amyloid oligomers on long-term potentiation (LTP) in murine hippocampal slices. Neuropharma-cology 60, 982-990.
63. Renner, M., Lacor, P. N., Velasco, P. T., Xu, J., Contractor, A., Klein, W. L., et al. (2010). Deleterious effects of amyloid beta oligomers acting as an extracellular scaffold for mGluR5. Neuron 66, 739-754.
64. Romano, C., van den Pol, A. N., and O'Malley, K. L. (1996). Enhanced early developmental expression of the metabotropic glutamate receptor mGluR5 in rat brain: protein, mRNA splice variants, and regional distribution. J. Comp. Neurol. 367, 403-412.
65. Ronesi, J. A., Collins, K. A., Hays, S. A., Tsai, N. P., Guo, W., Birnbaum, S. G., et al. (2012). Disrupted Homer scaffoldsmediate abnormalmGluR5 function in a mouse model of fragile X syndrome. Nat. Neurosci. 15, 431-440, S431.
66. Ronesi, J. A., and Huber, K. M. (2008). Homer interactions are necessaryfor metabotropic glutamate receptor-induced long-term depression and translational activation. J. Neurosci. 28, 543-547.
67. Rosenbrock, H., Kramer, G., Hob-son, S., Koros, E., Grundl, M., Grauert, M., et al. (2010). Functional interaction of metabotropic glutamate receptor 5 and NMDA-receptor by a metabotropic gluta-mate receptor 5 positive allosteric modulator. Eur. J. Pharmacol. 639, 40-46.
68. Sala, C., Roussignol, G., Meldolesi, J., and Fagni, L. (2005). Key role of the postsynaptic density scaffold proteins Shank and Homer in the functional architecture of Ca2+ homeostasis at dendritic spines in hippocampal neurons. J. Neurosci. 25, 4587-4592.
69. Sato, D., Lionel, A. C., Leblond, C. S., Prasad, A., Pinto, D., Walker, S., et al. (2012). SHANK1 deletions in males with autism spectrum disorder. Am. J. Hum. Genet. 90, 879-887.
70. Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., et al. (2008). Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 14, 837-842
71. Shigemoto, R., Kinoshita, A., Wada, E., Nomura, S., Ohishi, H., Takada, M., et al. (1997). Differential presy-naptic localization of metabotropic glutamate receptor subtypes in the rat hippocampus. J. Neurosci. 17, 7503-7522.
72. Silverman,J. L., Tolu,S. S., Barkan,C. L., and Crawley, J. N. (2010). Repetitive self-grooming behavior in the BTBR mouse modelof autismisblocked by the mGluR5 antagonist MPEP. Neuropsychopharmacology 35, 976-989.
73. Sokol, D. K., Maloney, B., Long, J. M., Ray, B., and Lahiri, D. K. (2011). Autism, Alzheimer disease, and fragile X: APP, FMRP, and mGluR5 are molecular links. Neurology 76, 1344-1352.
74. Stefani, M. R., and Moghaddam, B. (2010). Activation of type 5 metabotropic glutamate receptors attenuates deficits in cognitive flexibility induced by NMDA receptor blockade. Eur. J. Pharmacol. 639, 26-32.
75. Stoop, R., Conquet, F., and Pralong, E. (2003). Determination of group I metabotropic glutamate receptor subtypes involved in the frequency of epileptiform activity in vitro using mGluR1 and mGluR5 mutant mice. Neuropharmacology 44, 157-162.
76. Thomas, U. (2002). Modulation of synaptic signalling complexes by Homer proteins. J. Neurochem. 81, 407-413.
77. Tu, J. C., Xiao, B., Naisbitt, S., Yuan, J. P., Petralia, R. S., Brakeman, P., et al. (1999). Coupling of mGluR/Homer and PSD-95 complexes by the Shank family of postsynaptic density proteins. Neuron 23, 583-592.
78. Vardigan, J. D., Huszar, S. L., McNaughton, C. H., Hutson, P. H., and Uslaner, J. M. (2010). MK-801 produces a deficit in sucrose preference that is reversed by clozapine, D-serine, and the metabotropic glutamate 5 receptor positive allosteric modulator CDPPB: relevancetonegativesymp-toms associated with schizophrenia? Pharmacol. Biochem. Behav. 95, 223-229.
79. Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., et al. (2002). Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535-539.
80. Wang, H., Westin, L., Nong, Y., Birn-baum, S., Bendor, J., Brismar, H., et al. (2009). Norbin is an endogenous regulatorof metabotropicglutamate receptor 5 signaling. Science 326, 1554-1557.
81. Wang, Q., Walsh, D. M., Rowan, M. J., Selkoe, D. J., and Anwyl, R. (2004). Block of long-term potentiation by naturally secreted and synthetic amyloid beta-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. J. Neurosci. 24, 3370-3378.
82. Welsby, P., Rowan, M., and Anwyl, R. (2006). Nicotinic receptor-mediated enhancement of long-term poten-tiation involves activation of metabotropic glutamate receptors and ryanodine-sensitive calcium stores in the dentate gyrus. Eur. J. Neurosci. 24, 3109-3118
83. Wijetunge,L. S., Till,S. M., Gillingwater, T. H., Ingham, C. A., and Kind, P. C. (2008). mGluR5 regulates glutamate-dependent development of the mouse somatosen-sory cortex. J. Neurosci. 28, 13028-13037.
84. Won, H., Lee, H. R., Gee, H. Y., Mah, W., Kim, J. I., Lee, J., et al. (2012). Autistic-like social behaviour in Shank2-mutant mice improved by restoring NMDA receptor function. Nature 486, 261-265.
85. Yan, Q. J., Rammal, M., Tranfaglia, M., and Bauchwitz, R. P. (2005).Suppression of two major fragile X syndrome mouse model phe-notypes by the mGluR5 antagonist MPEP. Neuropharmacology 49, 1053-1066
86. Zirpel, L., Janowiak, M. A., Taylor, D. A., and Parks,T. N. (2000). Developmental changesinmetabotropicglu-tamate receptor-mediated calcium homeostasis. J. Comp. Neurol. 421, 95-106.